Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Published byJosef Kappel Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from."— Presentation transcript:

1 Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without an experimental therapy and a biomarker is present in 50% of the population under three scenarios: (A) a purely predictive biomarker; (B) a purely prognostic biomarker; and (C) a predictive and prognostic biomarker. For each scenario, the top row shows the overall population, and the two bottom rows show the biomarker-positive and biomarker-negative subgroups, respectively. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, mdz087, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Survival curves of the overall trial population from a hypothesized clinical trial with a predictive and ... Figure 2. Survival curves of the overall trial population from a hypothesized clinical trial with a predictive and prognostic biomarker with varying (A–C) biomarker prevalence, (D–F) biomarker prognostic effect, and (G) biomarker predictive effect. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, mdz087, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Kaplan–Meier estimates for overall survival derived from reconstructed data from RTOG 9402 [19], evaluating ... Figure 3. Kaplan–Meier estimates for overall survival derived from reconstructed data from RTOG 9402 [19], evaluating the addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiation therapy (RT) in patients with anaplastic oligodendroglioma and anaplastic oligoastrocystoma in the (A) overall population with (B) estimates of the hazard ratio over time with a 95% confidence interval. Kaplan–Meier estimates are also presented for patients (C) with 1p/19q co-deletion and (D) without the 1p/19q co-deletion. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Ann Oncol, mdz087, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from."

Similar presentations

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.
Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.
Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Figure 1 Flow diagram of the study

Figure 1 Flow diagram of the study
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Similar presentations

Ads by Google